NY AG Takes Up Pay-For-Delay Mantle With Teva Deal
By Melissa Lipman ( February 19, 2014, 7:27 PM EST) -- Generic-drug makers Teva Pharmaceuticals USA Inc. and Ranbaxy Pharmaceuticals Inc. on Wednesday promised to put an end to an agreement that kept them from challenging each other's so-called first-filer exclusivity periods, as part of a settlement with New York's attorney general that shows the watchdog's desire to push the reach of pay-for-delay case law....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.